Press release

Press release

February 3, 2016

Maximum dose level achieved, in clinical phase I/IIa study, without complications

The maximum dose level in Follicum’s clinical phase I/IIa study has now been administered to the first healthy volunteer without any negative effects being seen, achieving the study’s initial dose escalating part without any problems. The clinical study was initiated on 19 January 2016. The first participant in the study was administered with the maximum […]

January 22, 2016

Follicum Announces First Healthy Volunteer Dosed With FOL-005

On 19 January 2016 the first healthy volunteer received treatment with FOL-005, initiating the clinical phase I/IIa safety/efficacy study according to Follicum’s previously communicated time plan. Previously FOL-005 has shown effective inhibition of hair growth on living human skin tissue in vitro but this is the first time it has been used in man. Treatment of around […]

December 16, 2015

Approval to Start Clinical Study

Today Follicum obtained approval from the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and the research ethics committee to start a clinical Phase I/II a study. The study will now proceed according to the previously communicated plan. The study will be performed by the Clinical Research Center for Hair and Skin […]

November 30, 2015

Interim Report Q3 2015

Follicum today reported publication of its Q3 2015 interim report in Swedish. Below is a short summary of activities during the period: Significant activities during third quarter 2015: -On 1 September the company announced that the two toxicity studies which had been ongoing since March were completed, showing positive results. -In September Follicum initiated a collaboration […]

November 23, 2015

99.36% of Follicum’s TO 1 warrants converted

The utilization period of the TO 1 series warrants issued in conjunction with Follicum’s initial public offering ended on 17 November, warrants were converted at a rate of 99.36%. This provides additional funding of about 6.96 MSEK before issuing costs to Follicum. For more information, please contact Jan Alenfall, CEO Tel +46 (0) 46 19 […]

October 26, 2015

Information about warrants

Tomorrow, October 27, 2015, the utilization period of the series TO 1 warrants issued in conjunction with Follicum’s initial public offering starts. The utilization period will run until November 17, 2015. Warrant holders are entitled to subscribe for one new share in Follicum for each warrant at a price of SEK 6.00 per share. For more […]

October 23, 2015

New date for publication of Interim Report Q3

Follicum’s Interim Report for the Q3 period (1 July to 30 September 2015) will be published later than previously communicated.  The original date for publication was the 25 November 2015, but the new date for publication has been changed to 30 November 2015. For more information, please contact: Jan Alenfall, CEO Tel: +46 (0)46 19 […]

October 15, 2015

Clinical Trial Application filed to BfArM

Follicum has filed a clinical trial application to start a clinical Phase I / II a study to both the the BfArM (the Federal Institute for Drugs and  Medical Devices in Germany) and to the Research Ethics Committee. Follicum’s intention is to initiate the study at year-end 2015/early 2016, provided that the application is accepted. […]

October 1, 2015

Follicum’s patent preliminary approved

Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]